Esomeprazole: Uses, Dosage & Side Effects
Proton Pump Inhibitor (PPI) — Reduces stomach acid production
Quick Facts About Esomeprazole
Key Takeaways About Esomeprazole
- Potent acid reducer: Esomeprazole irreversibly blocks the proton pump in stomach cells, reducing acid production by up to 90% and providing sustained relief from heartburn, acid reflux, and ulcer-related pain
- Prescription medication: Esomeprazole generally requires a prescription, though low-dose formulations (Nexium Control 20 mg) may be available without prescription in some countries for short-term use
- Multiple formulations available: Available as enteric-coated tablets, granules for oral suspension (useful for children and patients with swallowing difficulties), and powder for intravenous injection in hospital settings
- Important drug interactions: Esomeprazole can interact with clopidogrel, warfarin, phenytoin, diazepam, certain antidepressants, and HIV medications. Always inform your healthcare provider about all medications you take
- Long-term risks to be aware of: Extended use may be associated with magnesium deficiency, vitamin B12 deficiency, increased fracture risk, and kidney inflammation. Regular medical review is essential for long-term users
What Is Esomeprazole and What Is It Used For?
Esomeprazole is a proton pump inhibitor (PPI) that works by irreversibly blocking the hydrogen/potassium ATPase enzyme system (the proton pump) in stomach parietal cells. As the S-enantiomer of omeprazole, it provides more predictable and slightly more potent acid suppression. It is used to treat gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and conditions involving excess stomach acid.
Esomeprazole belongs to a group of medications called proton pump inhibitors (PPIs), sometimes referred to as acid blockers or acid suppressants. It was first approved in 2000 and was developed as the purified S-enantiomer of omeprazole, one of the most widely used medications in the world. Omeprazole is a racemic mixture of two mirror-image forms (enantiomers): the S-enantiomer and the R-enantiomer. Research showed that the S-form is responsible for the majority of the acid-suppressing activity, and by purifying it, esomeprazole was designed to offer more consistent pharmacokinetics.
The medication works by targeting the final step of acid production in the parietal cells of the stomach lining. Unlike antacids, which simply neutralize existing stomach acid, or H2-receptor antagonists (such as ranitidine or famotidine), which reduce acid production through a different pathway, esomeprazole provides the most complete and sustained acid suppression available. A single daily dose can reduce gastric acid output by approximately 80–97% over 24 hours, depending on the dose and duration of treatment.
Esomeprazole undergoes less first-pass hepatic metabolism compared to racemic omeprazole, resulting in higher plasma concentrations and greater bioavailability. This means that a 20 mg dose of esomeprazole delivers more active drug to the target site than the equivalent 20 mg dose of omeprazole. In clinical studies, esomeprazole 40 mg demonstrated faster healing of erosive esophagitis and more complete resolution of heartburn symptoms compared to omeprazole 20 mg in the first weeks of treatment.
Common Indications
Esomeprazole is approved for the treatment of a range of acid-related gastrointestinal conditions. The specific indications may vary by country and formulation:
- Gastroesophageal reflux disease (GERD): Treatment of erosive esophagitis (healing and maintenance), as well as symptomatic GERD without esophageal damage. Esomeprazole reduces the backflow of acid into the esophagus, relieving symptoms such as heartburn, acid regurgitation, and chest pain, and promoting healing of damaged esophageal tissue.
- Peptic ulcer disease: Treatment of duodenal and gastric ulcers, including those associated with NSAID use. Esomeprazole accelerates ulcer healing by suppressing acid secretion and allowing the damaged mucosa to regenerate.
- Helicobacter pylori eradication: Used in combination with antibiotics (typically amoxicillin and clarithromycin) as part of triple therapy to eradicate H. pylori infection and heal associated ulcers. The acid suppression provided by esomeprazole increases antibiotic effectiveness in the stomach environment.
- Zollinger-Ellison syndrome: Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome, where gastrin-secreting tumors cause excessive acid production. Higher doses may be required in this setting.
- NSAID-associated ulcer prophylaxis: Prevention of gastric and duodenal ulcers in patients requiring chronic NSAID therapy who are at increased risk (e.g., elderly patients, those with a history of ulcers, or those also taking anticoagulants or corticosteroids).
- Pediatric GERD: In children aged 1 year and older, esomeprazole is approved for the treatment of GERD, including erosive esophagitis caused by acid reflux. Dosing is weight-based in younger children.
Esomeprazole is a prodrug that is converted to its active form in the strongly acidic environment of the gastric parietal cell canaliculi. Once activated, it forms an irreversible covalent bond with cysteine residues on the proton pump (H+/K+-ATPase), permanently disabling the enzyme. Because this inhibition is irreversible, acid secretion only resumes when the body synthesizes new proton pump molecules, a process that typically takes 24–72 hours. This is why the clinical effect of esomeprazole far outlasts its relatively short plasma half-life of approximately 1–1.5 hours.
What Should You Know Before Taking Esomeprazole?
Before taking esomeprazole, you should be aware of contraindications, potential warnings, and situations that require medical advice. Esomeprazole can mask symptoms of serious conditions including gastric cancer, so new or persistent digestive symptoms should always be evaluated by a healthcare provider before starting treatment.
While esomeprazole is generally well-tolerated and has an established safety profile, there are important considerations before starting treatment. Understanding these factors helps ensure safe and effective use of the medication and reduces the risk of adverse outcomes.
Contraindications
You should not take esomeprazole if any of the following apply:
- Allergy to esomeprazole or its ingredients: If you have a known hypersensitivity to esomeprazole, omeprazole, or any of the inactive ingredients in the formulation, you must not take this medication. Allergic reactions can range from mild skin rash to severe anaphylaxis.
- Allergy to other PPIs: If you are allergic to other proton pump inhibitors (such as pantoprazole, lansoprazole, rabeprazole, or omeprazole), cross-reactivity is possible and esomeprazole should be avoided or used only under close medical supervision.
- Concurrent use of nelfinavir: Esomeprazole must not be taken with nelfinavir (an HIV protease inhibitor), as esomeprazole significantly reduces nelfinavir plasma concentrations, potentially leading to HIV treatment failure and drug resistance.
- Previous severe skin reaction: If you have ever experienced a severe skin rash, skin peeling, blistering, or mouth sores after taking esomeprazole or a similar PPI, you must not take esomeprazole again.
Warnings and Precautions
Speak with your healthcare provider before taking esomeprazole if any of the following apply. These situations require careful medical assessment and may affect whether or how you can take this medication:
- Unintentional significant weight loss combined with difficulty swallowing
- Vomiting blood or material that resembles coffee grounds
- Black, tarry, or bloody stools
- Severe or persistent abdominal pain or indigestion
- Signs of severe allergic reaction: sudden wheezing, swelling of lips, tongue, throat, or body, difficulty breathing or swallowing
Esomeprazole treatment can mask the symptoms of other serious diseases, including gastric malignancy. Before starting treatment, your doctor should ensure that no serious underlying condition is present, particularly if you experience new or changed symptoms. Additionally, be aware of the following:
- Severe liver problems: If you have severe hepatic impairment, the maximum recommended dose of esomeprazole is 20 mg daily, as the drug is primarily metabolized by the liver and clearance is reduced in liver disease.
- Severe kidney problems: While no dose adjustment is generally required for renal impairment, patients with severely reduced kidney function should be monitored more closely, as there have been reports of interstitial nephritis with PPI use.
- Bone fracture risk: Prolonged use of PPIs, especially at high doses and for longer than one year, has been associated with a modest increase in the risk of hip, wrist, and spine fractures. Inform your doctor if you have osteoporosis or are taking corticosteroids, which may further increase fracture risk.
- Chromogranin A testing: If you are scheduled for blood tests measuring chromogranin A (used to investigate neuroendocrine tumors), inform your doctor that you are taking esomeprazole, as it can cause false-positive elevations. Ideally, esomeprazole should be discontinued at least 14 days before such testing.
Serious skin reactions: Rarely, esomeprazole has been associated with severe cutaneous adverse reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). If you develop a skin rash — particularly in areas exposed to sunlight — stop taking esomeprazole and seek immediate medical attention. Also mention any accompanying joint pain or other symptoms to your healthcare provider.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your healthcare provider before taking esomeprazole. Clinical data on esomeprazole use during pregnancy are limited, though available observational data for the racemic mixture (omeprazole) have not shown an increased risk of malformations or adverse pregnancy outcomes. Nevertheless, esomeprazole should only be used during pregnancy when clearly needed and when the potential benefit justifies the potential risk to the fetus.
It is not known whether esomeprazole passes into human breast milk. Because many drugs are excreted in milk, and because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue esomeprazole, taking into account the importance of the medication to the mother. Consult your healthcare provider for individual advice.
Driving and Operating Machinery
Esomeprazole is unlikely to affect your ability to drive or operate machinery. However, uncommon side effects such as dizziness, drowsiness, and visual disturbances have been reported. If you experience any of these symptoms, you should avoid driving or operating heavy machinery until the effects have resolved. You are personally responsible for assessing your fitness to drive or perform tasks requiring alertness.
Esomeprazole granules for oral suspension contain sucrose and glucose as excipients. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this formulation. Good oral hygiene and regular tooth brushing are recommended when using the granule formulation due to its sugar content.
How Does Esomeprazole Interact with Other Drugs?
Esomeprazole can interact with numerous medications because it affects gastric pH, is metabolized by cytochrome P450 enzymes (primarily CYP2C19 and CYP3A4), and can inhibit certain metabolic pathways. Always inform your doctor or pharmacist about all medications you are taking, including over-the-counter drugs and herbal supplements.
Drug interactions with esomeprazole occur through several mechanisms. By raising gastric pH, esomeprazole can alter the absorption of medications that require an acidic stomach environment. It is also metabolized by, and can inhibit, hepatic cytochrome P450 enzymes — particularly CYP2C19 — potentially affecting the metabolism of other drugs processed by the same pathways. Understanding these interactions is essential for safe prescribing and use.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, additional monitoring, or complete avoidance of concurrent use:
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Nelfinavir | Esomeprazole significantly reduces nelfinavir plasma levels | Contraindicated — do not use together |
| Clopidogrel | Esomeprazole inhibits CYP2C19 conversion of clopidogrel to its active metabolite | May reduce antiplatelet effect; avoid combination if possible |
| Atazanavir | Reduced absorption due to increased gastric pH | Avoid combination; may cause HIV treatment failure |
| Methotrexate (high-dose) | Esomeprazole may increase methotrexate levels by inhibiting renal elimination | Temporary discontinuation of esomeprazole may be required |
| Warfarin / Coumarin | Esomeprazole may increase warfarin effect via CYP2C19 inhibition | Monitor INR closely when starting or stopping esomeprazole |
| Phenytoin | Esomeprazole may increase phenytoin levels via CYP2C19 inhibition | Monitor phenytoin levels; dose reduction may be needed |
Other Notable Interactions
The following interactions require awareness and should be discussed with your healthcare provider. While they may be less critical than the major interactions above, they can still affect treatment outcomes:
| Drug | Effect | Action Required |
|---|---|---|
| Diazepam | Increased diazepam levels (CYP2C19 inhibition) | Monitor for excessive sedation |
| Citalopram / Imipramine / Clomipramine | Increased antidepressant levels (CYP2C19 inhibition) | May need dose reduction of antidepressant |
| Digoxin | Slightly increased digoxin absorption | Monitor digoxin levels in at-risk patients |
| Ketoconazole / Itraconazole / Voriconazole | Reduced antifungal absorption (pH-dependent) or increased esomeprazole levels (voriconazole) | Consider alternative antifungal; no dose adjustment needed for esomeprazole with voriconazole |
| Tacrolimus | Increased tacrolimus levels | Monitor tacrolimus levels closely |
| Cilostazol | Increased cilostazol and its active metabolite levels | Consider cilostazol dose reduction |
| Cisapride | Slightly increased cisapride levels | Use with caution; monitor for cardiac effects |
| Erlotinib | Reduced erlotinib absorption (pH-dependent) | Avoid concurrent use if possible |
| Rifampicin | Reduced esomeprazole levels (CYP enzyme induction) | May need higher esomeprazole dose |
| St. John’s Wort (Hypericum perforatum) | Reduced esomeprazole levels (CYP3A4 and CYP2C19 induction) | Avoid concurrent use |
Esomeprazole is primarily metabolized by the CYP2C19 enzyme, and its metabolism varies between individuals based on genetic differences. Approximately 2–6% of Caucasians and up to 15–20% of East Asian populations are "poor metabolizers" of CYP2C19 substrates, meaning they break down esomeprazole more slowly and achieve higher drug levels. However, because esomeprazole already undergoes less first-pass metabolism than racemic omeprazole, the variability between rapid and poor metabolizers is smaller with esomeprazole. No routine dose adjustment is required based on CYP2C19 status, though awareness of this variability may be important when evaluating drug interactions.
If your doctor has prescribed both antibiotics (amoxicillin and clarithromycin) and esomeprazole for treatment of Helicobacter pylori infection, it is particularly important to inform your doctor about all other medications you are taking, as the combination therapy may increase the risk of interactions.
What Is the Correct Dosage of Esomeprazole?
The recommended adult dose of esomeprazole for most conditions is 20–40 mg once daily. Dosing depends on the condition being treated, its severity, and patient factors such as age, weight, and liver function. Esomeprazole should be taken at least 30 minutes before a meal, and tablets should be swallowed whole with water.
Esomeprazole dosing varies depending on the specific condition being treated, the severity of symptoms, and patient-specific factors. The following guidelines represent standard dosing recommendations based on international prescribing information. Your healthcare provider may adjust your dose based on your individual circumstances, treatment response, and any concurrent medications.
Adults
| Condition | Dose | Duration |
|---|---|---|
| GERD (symptomatic, without erosive esophagitis) | 20 mg once daily | 4 weeks |
| Erosive esophagitis (healing) | 40 mg once daily | 4–8 weeks |
| Erosive esophagitis (maintenance) | 20 mg once daily | Long-term under medical review |
| Duodenal ulcer | 20 mg once daily | 2–4 weeks |
| Gastric ulcer | 20–40 mg once daily | 4–8 weeks |
| NSAID-associated ulcer (treatment) | 20 mg once daily | 4–8 weeks |
| NSAID-associated ulcer (prevention) | 20 mg once daily | As long as NSAID therapy continues |
| H. pylori eradication (triple therapy) | 20 mg twice daily + antibiotics | 7 days |
| Zollinger-Ellison syndrome | 40 mg twice daily (may increase up to 160 mg/day) | As clinically needed |
Children
Esomeprazole is approved for use in children for the treatment of GERD and H. pylori-associated ulcer disease. Dosing varies by age and body weight:
Children Aged 1–11 Years (GERD)
Esomeprazole granules for oral suspension are recommended for this age group:
- Body weight <20 kg: 10 mg once daily
- Body weight ≥20 kg: 10–20 mg once daily
The doctor will determine the exact dose based on the child’s weight and clinical response. Treatment duration is typically 8 weeks.
Children Aged 4 Years and Older (H. pylori Eradication)
Dosing is weight-based and determined by the treating physician. Esomeprazole is given alongside two antibiotics for 7 days. The combination and dosing will be adjusted by the doctor based on the child’s weight and local antibiotic resistance patterns.
Adolescents Aged 12 and Older
Adolescents may use adult dosing. Esomeprazole enteric-coated tablets or oral suspension can be used. Consult the prescribing physician for specific dosing advice.
Note: Esomeprazole is not recommended for children younger than 1 year of age. "As-needed" dosing has not been studied in children and is not recommended for pediatric patients.
Elderly Patients
No dose adjustment is generally required for elderly patients. Esomeprazole is well-tolerated in older adults. However, because elderly patients may be more susceptible to the long-term effects of acid suppression — including bone fracture risk, magnesium depletion, and vitamin B12 deficiency — regular medical review is recommended for those on prolonged therapy. Healthcare providers should use the lowest effective dose for the shortest duration necessary.
Patients with Liver Impairment
For patients with mild to moderate hepatic impairment, no dose adjustment is needed. For patients with severe hepatic impairment, the maximum recommended dose is 20 mg daily. For children aged 1–11 years with severe liver impairment, the maximum dose is 10 mg daily.
How to Take Esomeprazole
For optimal effectiveness, follow these instructions carefully:
- Enteric-coated tablets: Swallow whole with water. Do not crush, chew, or break the tablet. The enteric coating protects the active ingredient from stomach acid and ensures proper absorption in the small intestine. Take at least 30 minutes before a meal, preferably in the morning.
- Granules for oral suspension: Empty the contents of the sachet into a glass with 15 ml (approximately 3 teaspoons) of water per sachet. Use still water only — not carbonated water. Stir the granules and let the mixture stand for a few minutes until it thickens. Stir again and drink the entire contents. Do not chew or crush the granules. Rinse the glass with a little water and drink to ensure you receive the full dose. The suspension must be consumed within 30 minutes of preparation.
- Nasogastric tube administration: In hospital settings, esomeprazole granules can be administered through a nasogastric tube (French size 6 or larger). The granules are mixed with water, drawn into a syringe, and injected through the tube. The tube is then flushed with additional water to ensure complete delivery.
- Intravenous formulation: Esomeprazole 40 mg powder for injection is used in hospital settings when oral administration is not possible. It is given as a slow intravenous injection or infusion by healthcare professionals.
Missed Dose
If you forget to take a dose of esomeprazole, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to compensate for a missed one.
Overdose
If you suspect an overdose, or if a child has accidentally ingested esomeprazole, contact your local poison control center or seek emergency medical attention immediately. Limited data exist on very large overdoses of esomeprazole. Single doses of up to 280 mg have been reported with symptoms that were transient and mild, including nausea, vomiting, dizziness, abdominal pain, diarrhea, headache, and general weakness. There is no specific antidote; treatment is supportive and symptomatic. Esomeprazole is extensively protein-bound and is not readily removed by hemodialysis.
What Are the Side Effects of Esomeprazole?
Like all medications, esomeprazole can cause side effects, although most people tolerate it well. The most common side effects are headache, abdominal pain, diarrhea, nausea, vomiting, constipation, and flatulence. Serious side effects are rare but can include severe allergic reactions, liver problems, and severe skin reactions. Seek immediate medical attention if you experience any serious symptoms.
The following side effects have been reported with esomeprazole use. Side effects are classified by frequency according to standard medical convention. Most side effects are mild and resolve when the medication is stopped. However, some rare effects can be serious and require immediate medical attention.
- Yellowing of the skin or eyes (jaundice), dark urine, and fatigue — possible signs of liver problems (rare, up to 1 in 1,000 people)
- Sudden wheezing, swelling of lips, tongue, throat, or body, rash, faintness, or difficulty swallowing — signs of severe allergic reaction (rare, up to 1 in 1,000 people)
- Sudden, severe skin rash or redness with blistering or peeling, possibly with bleeding on lips, eyes, mouth, nose, or genitals — may be Stevens-Johnson syndrome, toxic epidermal necrolysis, or erythema multiforme (very rare, up to 1 in 10,000 people)
- Widespread rash with high fever and swollen lymph nodes — possible DRESS syndrome (very rare, up to 1 in 10,000 people)
Common Side Effects
- Headache
- Gastrointestinal symptoms: diarrhea, abdominal pain, constipation, flatulence (gas)
- Nausea and vomiting
- Benign gastric polyps (fundic gland polyps)
Uncommon Side Effects
- Swelling in the feet and ankles (peripheral edema)
- Sleep disturbances (insomnia)
- Dizziness, tingling or prickling sensations (paresthesia), drowsiness
- Vertigo (sensation of spinning)
- Dry mouth
- Elevated liver enzymes (on blood tests)
- Skin rash, hives (urticaria), or itching
- Hip, wrist, or spine fractures (with prolonged high-dose use)
Rare Side Effects
- Blood disorders: reduced white blood cells (leukopenia) or platelets (thrombocytopenia), causing weakness, bruising, or susceptibility to infections
- Low sodium levels in the blood (hyponatremia), causing weakness, vomiting, and cramps
- Agitation, confusion, depression
- Taste disturbances
- Visual disturbances (blurred vision)
- Sudden wheezing or shortness of breath (bronchospasm)
- Inflammation of the mouth (stomatitis)
- Oral thrush (candidiasis) — a fungal infection affecting the mouth or gut
- Liver problems including jaundice (yellowing of skin and eyes, dark urine)
- Hair loss (alopecia)
- Photosensitivity (skin rash triggered by sun exposure)
- Joint pain (arthralgia) and muscle pain (myalgia)
- General malaise and lack of energy
- Increased sweating
Very Rare Side Effects
- Agranulocytosis (severe reduction in white blood cells, weakening the immune system)
- Aggression
- Hallucinations
- Severe liver problems including liver failure and hepatic encephalopathy (brain inflammation due to liver failure)
- Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme (severe skin reactions)
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Muscle weakness
- Severe kidney inflammation (interstitial nephritis)
- Gynecomastia (breast enlargement in males)
Effects with Unknown Frequency
The following effects have been reported but their frequency cannot be estimated from available data:
- Hypomagnesemia: If esomeprazole is used for more than three months, blood magnesium levels may decrease. Low magnesium can manifest as fatigue, involuntary muscle movements, confusion, seizures, dizziness, and rapid heartbeat. Contact your doctor immediately if you experience any of these symptoms. Low magnesium can also lead to decreased potassium and calcium levels. Your doctor may recommend periodic blood tests to monitor magnesium levels.
- Colitis: Inflammation of the intestine causing diarrhea, which may be associated with Clostridioides difficile infection.
- Skin rash with joint pain: A rash that may be accompanied by pain in the joints.
In very rare cases, esomeprazole may affect the white blood cells, leading to immune deficiency. If you develop an infection with symptoms such as fever with severely impaired general condition, or fever with symptoms of a local infection such as sore throat, mouth ulcers, or urinary problems, contact your doctor immediately so that blood tests can be performed to rule out agranulocytosis. It is important to inform healthcare professionals about your medication at that time.
If you experience any side effects, including those not listed above, report them to your healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting helps ensure the ongoing safety monitoring of medications.
How Should You Store Esomeprazole?
Esomeprazole tablets and granules do not require any special storage conditions. Keep out of sight and reach of children. Do not use after the expiration date. Prepared suspension (from granules) must be used within 30 minutes.
Proper storage of esomeprazole ensures the medication remains effective and safe to use throughout its shelf life. Although the product does not require specific temperature or humidity conditions for the unopened packaging, common-sense storage practices should be followed:
- Temperature: Store at room temperature. Avoid exposure to excessive heat or freezing.
- Moisture protection: Keep esomeprazole in its original packaging to protect from humidity. Do not remove tablets from blister packs until you are ready to take them.
- Light: Store in a location protected from direct sunlight.
- Children: Keep out of sight and reach of children at all times.
- Expiration: Do not use esomeprazole after the expiration date printed on the outer carton and sachet. The expiration date refers to the last day of the indicated month.
- Prepared suspension: Once the granules have been mixed with water, the suspension must be consumed within 30 minutes. Do not store the prepared suspension for later use.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused medications to a pharmacy for proper disposal to help protect the environment.
What Does Esomeprazole Contain?
Esomeprazole products contain the active substance esomeprazole (as esomeprazole magnesium trihydrate). The inactive ingredients (excipients) provide structural integrity, protect the active ingredient from stomach acid, and ensure proper drug release in the intestine. Exact formulations vary between product types and manufacturers.
Understanding what is in your medication can help identify potential allergens or intolerances. The inactive ingredients vary between different formulations (tablets, granules, injection) and between different manufacturers of generic products.
Active Ingredient
The active substance is esomeprazole, provided as esomeprazole magnesium trihydrate. Each dosage unit contains 10 mg, 20 mg, or 40 mg of esomeprazole, depending on the product strength. Esomeprazole is the S-enantiomer of the substituted benzimidazole omeprazole.
Common Excipients (Granules for Oral Suspension)
The granule formulation typically contains the following inactive ingredients:
- Glycerol monostearate 40-55 (emulsifier)
- Hydroxypropyl cellulose (binder)
- Hypromellose (coating agent)
- Magnesium stearate (lubricant)
- Methacrylic acid-ethyl acrylate copolymer (enteric coating)
- Polysorbate 80 (surfactant)
- Sugar spheres containing sucrose and maize starch (core)
- Talc (anti-caking agent)
- Triethyl citrate (plasticizer)
- Citric acid anhydrous (pH adjustment)
- Crospovidone (disintegrant)
- Glucose (sweetener)
- Yellow iron oxide E172 (colorant)
- Xanthan gum (thickener)
Important: The granule formulation contains both sucrose and glucose. Maintaining good oral hygiene and regular tooth brushing is recommended. If you have been told by your doctor that you have an intolerance to certain sugars, contact your healthcare provider before taking this formulation.
Appearance
Esomeprazole granules for oral suspension appear as pale yellow small granules. Some brownish granules may be present, which is normal. When mixed with water, the suspension forms a thick yellow liquid with suspended granule particles. Enteric-coated tablets are typically light pink to brownish-red, depending on the manufacturer and strength.
Frequently Asked Questions About Esomeprazole
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Nexium (esomeprazole) — Summary of Product Characteristics." EMA Official European regulatory documentation for esomeprazole (Nexium).
- U.S. Food and Drug Administration (FDA). "Nexium (esomeprazole magnesium) — Prescribing Information." FDA FDA-approved labeling and safety information for esomeprazole.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines — 23rd list." WHO Essential Medicines Proton pump inhibitors listed as essential medicines for acid-related disorders.
- British National Formulary (BNF). "Esomeprazole: Indications, dose, contraindications, side effects, interactions." BNF / NICE Comprehensive UK drug monograph including dosing and interaction data.
- Kahrilas PJ, et al. (2000). "Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients." Alimentary Pharmacology & Therapeutics. 14(10):1249–1258. doi:10.1046/j.1365-2036.2000.00836.x Landmark comparative study of esomeprazole vs omeprazole for erosive esophagitis.
- Freedberg DE, et al. (2017). "The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association." Gastroenterology. 152(4):706–715. doi:10.1053/j.gastro.2017.01.031 AGA best practice advice on long-term PPI use, risks, and benefits.
- Malfertheiner P, et al. (2022). "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report." Gut. 71:1724–1762. doi:10.1136/gutjnl-2022-327745 International consensus guidelines on H. pylori eradication therapy including PPI-based regimens.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in gastroenterology, pharmacology, and clinical medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Gastroenterology Specialists
Licensed physicians specializing in gastroenterology and hepatology, with documented experience in acid-related disorders and pharmacological treatment.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing.
Researchers
Academic researchers with published peer-reviewed articles on proton pump inhibitors and gastrointestinal pharmacotherapy.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in gastroenterology, pharmacology, internal medicine, and clinical research.